ALK and non-small cell lung carcinoma: Rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene occur in 5% to 6% of NSCLC patients, resulting in increased expression of ALK, which triggers epithelial-mesenchymal transition (EMT) and enhances migration and invasion.